- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05920577
Effects of Exergames and Resistance Training
Effects of the Combined Use of Exergaming and Resistance Training in Improving the Frailty of Nursing Home Residents: A Pilot Randomised Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Frailty is a common geriatric condition with significantly increased vulnerability to stress and susceptibility of negative health-related outcomes. The prevalence rates of frailty varies across countries, and the pooled estimates of prevalence rates of 52.3% and 40.2% of frailty and prefrailty were reported among nursing home residents respectively. Previous studies also revealed that frailty is predictive for various adverse health outcomes.
Sacropenia is a major etiologic risk factor to frailty. It refers to an age-related generalised muscle disorder featuring with loss of muscle mass and function5. Talar et al systematically reviewed and meta-analysed 25 randomised controlled trials (RCTs) using resistance training among 2,267 older people (age >65 years) with pre-sarcopenia, sarcopenia, pre-frailty or frailty. It was revealed that, compared to control, resistance training with at least 8 weeks intervention period had small to large effects in improving handgrip strength, lower-limb strength, agility, gait speed, postural stability, functional performance, fat mass and muscle [Effect size (ES) = 0.29 - 0.93, p <0.001 to = 0.007].
Cognitive impairment is another major risk factor for declined frailty status among prefrail older people. Non-frail older people are known to have better performance on cognitive status, including processing speed, executive function, attention and working memory, immediate memory and delayed memory (g = 0.320 to 0.64), than frail older people. Ample research evidence suggested that cognition predicts the incidence of frailty.
Exergaming is a fast growing research trend in gerontechnology and several commercial exergaming consoles, such as the Xbox system (including Xbox One and Xbox 360) and Nintendo Will (Wii Sports and Wii Fit), are available. Ogawa et al systematically reviewed 7 clinical trials (5 RCTs and 2 uncontrolled studies) and revealed that exergaming could improve cognitive functions, including executive function, process speed and reaction time, of older people. Moreover, a recent RCT revealed that, compared with the combined use of exercise (resistance, aerobic and balance training), a 12 week Kinect-based exergaming could better improve the global cognition [F(1, 44) = 5.277, p = 0.026] as measured by the Montreal Cognitive Assessment of community-frail older people. The Kinect-based group (n = 25) also demonstrated significant improvement in verbal (p < 0.05) and working (p < 0.05) memory post-intervention but the combined exercise group (n = 21) did not.
Given that sacropenia and impaired cognitive function are 2 major contributors to frailty; and exergaming and resistance training are effective treatments in improving the cognitive function and sacropenia of older people respectively, this study aims to evaluate the effects of the combined use of exergaming and resistance training in improving the frailty of nursing home residents.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Liu Tai Wa, PhD
- Phone Number: 00852 39708714
- Email: twliu@hkmu.edu.hk
Study Contact Backup
- Name: Candy Leung
- Phone Number: 00852 27686251
- Email: chileung@hkmu.edu.hk
Study Locations
-
-
-
Ho Man Tin, Hong Kong
- Recruiting
- Jockey club Institute of Health
-
Contact:
- Liu TW, PhD
- Phone Number: 39708714
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- living in a nursing home
- fulfilled 1, 2 or 3 Fried Criteria of frailty
- score ≥7 of 10 on the Chinese version of the Abbreviated Mental Test
- able to follow the instructions of assessment and intervention
Exclusion Criteria:
- involved in any drug or other clinical trials
- having any additional medical conditions (such as epilepsy)
- unable to walk independently without the use of walking aids
- having any other conditions that will hinder the assessment and intervention (e.g.,visual/audio impairment could not be corrected by glasses/hearing aids etc).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exergames and resistance training group
Participants will receive exergaming and resistance training programme over a period of 12 weeks
|
In each session, the participants will receive 40 minutes of combined use of exergaming and resistance training.
The participants will practice the exergames using the gaming system Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan).
The gaming software "Nintendo Switch Sports" will be adopted in which arrays of exergames are available to strengthen both the upper and lower extremity muscle and improve the balance ability of participants.
The exergaming programme will consist of both upper (badminton game and tennis game) and lower (soccer game) extremity games.
For week 1 and 2, the participants will first practice 1-minute warm up exercise (stretching exercises) and then the 3 exergames.
For week 3 to 12, the participants will receive the same warm up exercise and exergames as if week 1 and 2 but there will be an addition of light cuff weight for resistance training.
|
Active Comparator: Resistance training group
Participants will receive resistance training programme over a period of 12 weeks
|
The resistance training programme consists of 2 parts, the upper limb and lower limb resistance exercises.
For the upper limb resistance exercises, the participants will first practice 5-minute warm up of upper limb using ergometer and then undergo 2 resistance exercises, including handgrip and elbow flexion.
For the lower limb exercise, the participants will also first practice 5-minute warm up of lower limb using ergometer and then undergo 3 resistance exercises, including squatting, single-leg standing and knee extension.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Muscle quantity, higher score means better muscle quantity
Time Frame: T1: baseline (before the study begins)
|
Will be assessed using a bioelectrical impedance measurement
|
T1: baseline (before the study begins)
|
Change from baseline muscle quantity at 6 weeks
Time Frame: T2: mid-intervention (week 6)
|
Will be assessed using a bioelectrical impedance measurement
|
T2: mid-intervention (week 6)
|
Muscle strength, higher score means better muscle strength
Time Frame: T1: baseline (before the study begins)
|
Will be assessed using a handheld dynamometer
|
T1: baseline (before the study begins)
|
Change from baseline muscle strength at 6 weeks
Time Frame: T2: mid-intervention (week 6)
|
Will be assessed using a handheld dynamometer
|
T2: mid-intervention (week 6)
|
Change from baseline muscle strength at 12 weeks
Time Frame: T3: post-intervention (week 12)
|
Will be assessed using a handheld dynamometer
|
T3: post-intervention (week 12)
|
Change from baseline muscle strength at 16 weeks
Time Frame: T4: 1 month follow up (week 16)
|
Will be assessed using a handheld dynamometer
|
T4: 1 month follow up (week 16)
|
Change from baseline muscle strength at 24 weeks
Time Frame: T5: 3 months follow up (week 24)
|
Will be assessed using a handheld dynamometer
|
T5: 3 months follow up (week 24)
|
Lower Extremity functions, higher scores mean better lower extremity functions
Time Frame: T1: baseline (before the study begins)
|
Will be assessed using the Short Physical Performance Battery
|
T1: baseline (before the study begins)
|
Change from baseline lower extremity functions at 6 weeks
Time Frame: T2: mid-intervention (week 6)
|
Will be assessed using the Short Physical Performance Battery
|
T2: mid-intervention (week 6)
|
Change from baseline lower extremity functions at 12 weeks
Time Frame: T3: post-intervention (week 12)
|
Will be assessed using the Short Physical Performance Battery
|
T3: post-intervention (week 12)
|
Change from baseline lower extremity functions at 16 weeks
Time Frame: T4: 1 month follow up (week 16)
|
Will be assessed using the Short Physical Performance Battery
|
T4: 1 month follow up (week 16)
|
Change from baseline lower extremity functions at 24 weeks
Time Frame: T5: 3 months follow up (week 24)
|
Will be assessed using the Short Physical Performance Battery
|
T5: 3 months follow up (week 24)
|
Change from baseline muscle quantity at 12 weeks
Time Frame: T3: post-intervention (week 12)
|
Will be assessed using a bioelectrical impedance measurement
|
T3: post-intervention (week 12)
|
Change from baseline muscle quantity at 16 weeks
Time Frame: T4: 1 month follow up (week 16)
|
Will be assssed using a bioelectrical impedance measurement
|
T4: 1 month follow up (week 16)
|
Change from baseline muscle quantity at 24 weeks
Time Frame: T5: 3 months follow up (week 24)
|
Will be assssed using a bioelectrical impedance measurement
|
T5: 3 months follow up (week 24)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive function, higher score means better cognitive function
Time Frame: T1: baseline (before the study begins)
|
Will be assessed using the Montreal Cognitive Assessment (HK version)
|
T1: baseline (before the study begins)
|
Change from baseline cognitive function at 6 weeks
Time Frame: T2: mid-intervention (week 6)
|
Will be assessed using the Montreal Cognitive Assessment (HK version)
|
T2: mid-intervention (week 6)
|
Change from baseline cognitive function at 12 weeks
Time Frame: T3: post-intervention (week 12)
|
Will be assessed using the Montreal Cognitive Assessment (HK version)
|
T3: post-intervention (week 12)
|
Change from baseline cognitive function at 16 weeks
Time Frame: T4: 1 month follow up (week 16)
|
Will be assessed using the Montreal Cognitive Assessment (HK version)
|
T4: 1 month follow up (week 16)
|
Change from baseline cognitive function at 24 weeks
Time Frame: T5: 3 months follow up (week 24)
|
Will be assessed using the Montreal Cognitive Assessment (HK version)
|
T5: 3 months follow up (week 24)
|
Mobility, longer time means worse funcitonal mobility
Time Frame: T1: baseline (before the study begins)
|
Will be assessed using the Timed Up and Go Test
|
T1: baseline (before the study begins)
|
Change from baseline mobility at 6 weeks
Time Frame: T2: mid-intervention (week 6)
|
Will be assessed using the Timed Up and Go Test
|
T2: mid-intervention (week 6)
|
Change from baseline mobility at 12 weeks
Time Frame: T3: post-intervention (week 12)
|
Will be assessed using the Timed Up and Go Test
|
T3: post-intervention (week 12)
|
Change from baseline mobility at 16 weeks
Time Frame: T4: 1 month follow up (week 16)
|
Will be assessed using the Timed Up and Go Test
|
T4: 1 month follow up (week 16)
|
Change from baseline mobility at 24 weeks
Time Frame: T5: 3 months follow up (week 24)
|
Will be assessed using the Timed Up and Go Test
|
T5: 3 months follow up (week 24)
|
Frailty, score range 0 to 9, higher score means higher level of frailty
Time Frame: T1: baseline (before the study begins)
|
Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
|
T1: baseline (before the study begins)
|
Change from baseline frailty at 6 weeks
Time Frame: T2: mid-intervention (week 6)
|
Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
|
T2: mid-intervention (week 6)
|
Change from baseline frailty at 12 weeks
Time Frame: T3: post-intervention (week 12)
|
Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
|
T3: post-intervention (week 12)
|
Change from baseline frailty at 16 weeks
Time Frame: T4: 1 month follow up (week 16)
|
Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
|
T4: 1 month follow up (week 16)
|
Change from baseline frailty at 24 weeks
Time Frame: T5: 3 months follow up (week 24)
|
Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C)
|
T5: 3 months follow up (week 24)
|
Sarcopenia, score ranged from 0 to 20, lower score means lower risk
Time Frame: T1: baseline (before the study begins)
|
Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls(SARC-Calf)
|
T1: baseline (before the study begins)
|
Change from baseline sarcopenia at 6 weeks
Time Frame: T2: mid-intervention (week 6)
|
Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf)
|
T2: mid-intervention (week 6)
|
Change from baseline sarcopenia at 12 weeks
Time Frame: T3: post-intervention (week 12)
|
Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls(SARC-Calf)
|
T3: post-intervention (week 12)
|
Change from baseline sarcopenia at 16 weeks
Time Frame: T4: 1 month follow up (week 16)
|
Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf)
|
T4: 1 month follow up (week 16)
|
Change from baseline sarcopenia at 24 weeks
Time Frame: T5: 3 month follow up (week 16)
|
Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf)
|
T5: 3 month follow up (week 16)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Frailty_2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frailty
-
University of PennsylvaniaCompleted
-
Instituto Tecnologico y de Estudios Superiores...Not yet recruiting
-
Longeveron Inc.CompletedAging FrailtyUnited States
-
Longeveron Inc.CompletedAging FrailtyUnited States
-
The Hong Kong Polytechnic UniversityCompleted
-
Xijing HospitalUnknownFrailty SyndromeChina
-
Region ZealandUniversity of Southern DenmarkActive, not recruitingFrailty SyndromeDenmark
-
Neurological Associates of West Los AngelesEnrolling by invitation
-
IRCCS Centro San Giovanni di Dio FatebenefratelliCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
Clinical Trials on exergames and resistance training
-
University of FloridaCompleted
-
University of KasselCompleted
-
University of KasselUniversity of PotsdamCompleted
-
University of Alabama at BirminghamCompletedMusculoskeletal and Metabolic CrosstalkUnited States
-
University of Applied Sciences of Western SwitzerlandCompleted
-
University of BarcelonaCompleted
-
Vienna Hospital AssociationRecruiting
-
Universidade Federal de Sao CarlosConselho Nacional de Desenvolvimento Científico e TecnológicoCompletedChronic Obstructive Pulmonary DiseaseBrazil
-
Universidade Federal do Triangulo MineiroUnknown
-
Riphah International UniversityCompletedSports Physical Therapy | Anthropometric Measurements and Elastic Resistance TrainingPakistan